酒石酸双氢可待因片治疗中重度癌痛疼痛程度的影响-国际医药研究前沿-CSCIED科技核心评价数据库-手机版

酒石酸双氢可待因片治疗中重度癌痛疼痛程度的影响

Effect of dihydrocodeine tartrate tablets on pain degree of moderate and severe cancer pain

ES评分 0 浏览量：841 下载量：0

DOI	10.12208/j.imrf.20220125
刊名	国际医药研究前沿 International Medical Research Frontier
年，卷(期)	2022, 6(4)
作者	徐刚*,
作者单位	北京大学肿瘤医院北京 ;
摘要	分析探讨酒石酸双氢可待因片治疗中重度癌痛疼痛程度的影响效果。方法选取我院2020年-2021年接受治疗患者且存在中重度癌痛患者120例为观察对象，所有患者均采用酒石酸双氢可待因片治疗，将患者治疗后的疼痛缓解率、不良反应发生率进行统计，并将治疗前后的生存质量进行比较。结果 120例患者中，完全缓解为53例，占44.2%，占比最多，总缓解率为100.0%；5例患者出现不良反应情况，占4.2%，患者症状较轻，经对症治疗后已痊愈；相较于治疗前，患者治疗后生存质量明显提升，存在显差异（P<0.05）。结论采用酒石酸双氢可待因片治疗中重度癌痛患者能够有效降低疼痛程度，避免出现不良反应，获得较高的生存质量，临床疗效明显，值得在临床治疗中推广应用。
Abstract	Objective To analyze the effect of dihydrocodeine tartrate tablets in the treatment of moderate and severe cancer pain. Methods 120 patients with moderate to severe cancer pain who were treated in our hospital from 2020 to 2021 were selected as the observation objects. All patients were treated with dihydrocodeine tartrate tablets. The pain relief rate and adverse reaction rate of patients after treatment were counted, and the quality of life before and after treatment were compared. Results among the 120 patients, 53 patients had complete remission, accountting for 44.2%, accounting for the most, and the total remission rate was 100.0%; Five patients had adverse reactions, accounting for 4.2%. The patients had mild symptoms and recovered after symptomatic treatment; Compared with before treatment, the quality of life of patients after treatment was significantly improved (P<0.05). Conclusion dihydrocodeine tartrate tablets can effectively reduce the degree of pain, avoid adverse reactions, and obtain higher quality of life in patients with moderate and severe cancer pain. It has obvious clinical effect and is worth popularizing in clinical treatment.
关键词	酒石酸双氢可待因片；中重度癌痛；疼痛程度；影响效果
KeyWord	Dihydrocodeine tartrate tablets; Moderate and severe cancer pain; Degree of pain; Impact effect
基金项目
页码	1-3

参考文献
相关文献

[1] 刘雪娇,滕蕾,邹慧超,等.鞘内药物输注系统植入术在难治性癌痛治疗中的应用一例[J].中国临床案例成果数据库, 2022,04(01):071-071.

[2] 沙淑喜.麻醉镇痛药在癌痛治疗中对癌痛患者治疗前,后的疼痛情况及生活质量的影响[J].中国保健营养,2020,30(19):3.

[3] 隋小静,李世林,曹建英,等.氨酚双氢可待因片致过敏性休克1例[J].中国现代应用药学,2019,36(19):2.

[4] 韦阿琛.癌痛患者疼痛门诊药物治疗的临床效果分析[J].健康之友,2020年6期,291页, 2020.

[5] 于丽丽.研究全程疼痛护理干预对癌痛患者睡眠和服药依从性的影响[J].家有孕宝,2021,3(12):273.

[6] 傅华容,黄妙芳,辜赛花,等.疼痛护理对直肠癌癌痛患者不良情绪及爆发性疼痛的影响[J].广州医药,2022,53(2):6.

[7] 张生茂,李娜,包娜日素,等.盐酸氢吗啡酮治疗骨癌痛患者的临床效果及对疼痛相关介质和激素水平的影响[J].中国医药导报,2022,19(1):5.

[8] 程慧勇.盐酸羟考酮缓释片对晚期恶性肿瘤癌痛患者疼痛程度及生命质量的影响[J].医疗装备,2020,33(20):2.

[9] 曾媛.度洛西汀联合羟考酮缓释片,唑来膦酸治疗骨转移中重度神经病理性癌痛的疗效观察[J].癌症进展,2021,19(8):5.

[10] 万复甦,董爽,蔡茜,等.低剂量氨酚羟考酮片与可待因治疗中度骨转移癌痛的随机对照研究[J].肿瘤防治研究,2019,046(007):632-634.

引用本文

徐刚*. 酒石酸双氢可待因片治疗中重度癌痛疼痛程度的影响 [J]. 国际医药研究前沿. 2022; 6; (4). 1 - 3.

文献评论

相关学者

相关机构